Research & Regulatory News

MHRA Drug Safety Update: Semaglutide and NAION

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

The MHRA issued a Drug Safety Update on 5 February 2026 warning of a likely association between semaglutide (Wegovy, Ozempic and Rybelsus) and non-arteritic anterior ischaemic optic neuropathy. A European review estimated the frequency at up to 1 in 10,000 people taking it.

Key facts

Issued
5 February 2026
Regulator
MHRA (United Kingdom)
Products
Wegovy, Ozempic, Rybelsus
Condition
Non-arteritic anterior ischaemic optic neuropathy
Estimated frequency
Up to 1 in 10,000
Presentation
Sudden painless vision loss in one eye
Action if confirmed
Discontinue semaglutide

What NAION is

Non-arteritic anterior ischaemic optic neuropathy is damage to the optic nerve head caused by reduced blood supply, not by inflammation of the arteries, which is what the non-arteritic distinction means. It typically presents as sudden, painless loss or blurring of vision in one eye. It is uncommon in the general population and the visual loss is frequently permanent.

What the MHRA said

The Drug Safety Update of 5 February 2026 describes a likely association between semaglutide and NAION across all three UK products: Wegovy, Ozempic and Rybelsus. A European review estimated the frequency at up to 1 in 10,000 people taking semaglutide, which places it in the very rare category. The guidance is that patients presenting with these symptoms should be urgently referred for specialist ophthalmological examination, and that semaglutide should be discontinued if NAION is confirmed.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The detail specific to the UK market

The update makes a point that says a great deal about how these medicines are actually obtained here: semaglutide may not appear on a patient's medical record when it has been privately prescribed, so anyone presenting with these symptoms should be asked directly about semaglutide use. A large private prescription market means the drug history in front of a clinician may be incomplete, and the guidance is written around that reality rather than around an idealised record.

Where the signal came from

The published work behind it includes a 2024 study in JAMA Ophthalmology by Hathaway and colleagues examining NAION risk in patients prescribed semaglutide, followed by further analysis by Cai and colleagues in the same journal in 2025. A regulator issuing a safety update on that basis is the pharmacovigilance system working as designed: a signal detected, investigated, and communicated with a frequency estimate attached.

How to read a 1-in-10,000 estimate

Very rare, and that needs careful reading in both directions. It does not mean the association is unimportant. Permanent vision loss is a serious outcome and the population taking semaglutide is very large, so a rare event across millions of users is not a small number of people. It also does not mean the risk is established as causal; regulators use language such as likely association because the evidence supports action without establishing mechanism.

What this has to do with research material

Nothing directly, and the distinction is worth making. This is a safety communication about licensed medicines prescribed to patients and monitored through a pharmacovigilance system. Material supplied for laboratory research sits outside that system entirely, which is a limitation of research material rather than a reassurance about it. There is no equivalent monitoring, no Yellow Card signal detection, and no regulator issuing updates.

Frequently asked questions

How common is NAION with semaglutide?

A European review estimated up to 1 in 10,000 people taking it, which is the very rare category. The MHRA describes it as a likely association.

What should someone do if they have symptoms?

The MHRA guidance is urgent referral for specialist ophthalmological examination. This is a clinical matter for a prescriber, not something to self-assess.

Why does the MHRA mention private prescriptions?

Because privately prescribed semaglutide may not appear on a patient's medical record, so a clinician may not know it is being taken unless they ask.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.